For which patient groups is this injection suitable?

It is suitable for elderly and adult patients.

What are the available payment terms?

Payment terms include LC and T/T.

What is the average lead time for orders?

The average lead time is one month during peak season.

Azithromycin Injection Macrolides Antibiotics Powder for Injection

Name: Azithromycin Injection Macrolides Antibiotics Powder for Injection
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 1924351855

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.50-1.00

10,000 vial

Sample price:US$1.00/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Model NO.

0.25g 0.5g

Suitable for

Elderly, Adult

State

Solid

Shape

Powder

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Production Line

GMP Approved

Transport Package

Carton

Specification

10 vials each box and 20 boxes each carton

Trademark

SHIMEN

Origin

Hebei

HS Code

3004909099

Production Capacity

1 Million

Key features

GMP Approved Production: Manufactured on GMP approved production lines ensuring strict quality control.

Chemical Synthesis Technology: Produced using advanced chemical synthesis pharmaceutical technology.

Respiratory Infection Treatment: Mainly used for respiratory tract infections caused by susceptible bacteria.

Skin and Soft Tissue Infection Treatment: Effective treatment for skin soft tissue infections and Chlamydia transmitted diseases.

White Crystalline Powder: Appears as white or almost white crystalline powder, odorless and bitter.

Global Market Presence: Products sold to over 80 countries and regions worldwide.

Full Automation Control: Production lines feature full automation and information control.

70-Year Company History: Established in 1948 with a 70-year history in pharmaceutical R&D and manufacturing.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.